CollPlant Biotechnologies (CLGN) FCF Margin (2018 - 2025)
CollPlant Biotechnologies' (CLGN) quarterly FCF Margin came in at 4866.67% in Q4 2025, down 279045.0% YoY from N/an in Q4 2024, and down 30.3% on a QoQ basis from 3735.06% in Q3 2025.
CollPlant Biotechnologies (CLGN) FCF Margin (2018 - 2025) Analysis & Trends
CollPlant Biotechnologies (CLGN) has 8 years of FCF Margin data on file, last reported at 4866.67% in Q4 2025.
- Quarterly FCF Margin fell 279045.0% year-over-year to 4866.67% in Q4 2025, while the trailing twelve-month figure through Mar 2026 was 2116.45% (down 169416.0% YoY) and the FY2025 annual result came in at 396.08%, up 224664.0% from the prior year.
- FCF Margin retreated to 4866.67% in Q4 2025, from 3735.06% in the prior quarter.
- In the past five years, FCF Margin ranged from a high of 77.52% in Q1 2021 to a low of 82700.0% in Q3 2024.
- A 5-year average of 7373.63% and a median of 1538.19% in 2021 frame the typical range for FCF Margin.
- Annual changes were most pronounced in 2024 — FCF Margin slumped 8270002 bps — and 2025, when it jumped 7896494 bps.
- Tracing CLGN's FCF Margin over 5 years: stood at 320.0% in 2021, then slumped by 6594 bps to 21420.69% in 2022, then surged by 97 bps to 707.69% in 2023, then plunged by 193 bps to 2076.22% in 2024, then tumbled by 134 bps to 4866.67% in 2025.
- The last three FCF Margin figures came in at 4866.67% (Q4 2025), 3735.06% (Q3 2025), and 1361.45% (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 30.39% |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 13.35% |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -388.28% |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 25.68% |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 22.62% |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -22.35% |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 70.82% |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 41.07% |
| 10 | CollPlant Biotechnologies | 4.13 Mn | 4.13 Mn | -243,000.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -4,866.67% |
| Sep 30, 2025 | -3,735.06% |
| Jun 30, 2025 | -1,361.45% |
| Dec 31, 2024 | -2,076.22% |
| Sep 30, 2024 | -82,700.00% |
| Jun 30, 2024 | -1,496.39% |
| Mar 31, 2024 | -3,235.71% |
| Dec 31, 2023 | -707.69% |
| Sep 30, 2023 | 0.02% |
| Jun 30, 2023 | -33.45% |
| Mar 31, 2023 | -763.28% |
| Dec 31, 2022 | -21,420.69% |
| Sep 30, 2022 | -2,638.53% |
| Jun 30, 2022 | -5,413.64% |
| Dec 31, 2021 | -320.00% |
| Sep 30, 2021 | -1,580.00% |
| Jun 30, 2021 | -454.12% |
| Mar 31, 2021 | 77.52% |
| Dec 31, 2020 | -65.47% |
| Sep 30, 2020 | -33,823.53% |